Astellas Pharma Inc. (4503.T)
JPY 1521.5
(0.8%)
JPY 1521.5
(0.8%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1603.67 Billion JPY | 5.6% |
| 2022 | 1518.61 Billion JPY | 17.16% |
| 2021 | 1296.16 Billion JPY | 3.73% |
| 2020 | 1249.52 Billion JPY | -3.94% |
| 2019 | 1300.84 Billion JPY | -0.42% |
| 2018 | 1306.34 Billion JPY | 0.46% |
| 2017 | 1300.31 Billion JPY | -0.87% |
| 2016 | 1311.66 Billion JPY | -4.45% |
| 2015 | 1372.7 Billion JPY | 10.06% |
| 2014 | 1247.25 Billion JPY | 9.42% |
| 2013 | 1139.9 Billion JPY | 13.35% |
| 2012 | 1005.61 Billion JPY | 3.74% |
| 2011 | 969.38 Billion JPY | 1.62% |
| 2010 | 953.94 Billion JPY | -2.15% |
| 2009 | 974.87 Billion JPY | 0.95% |
| 2008 | 965.69 Billion JPY | -0.71% |
| 2007 | 972.58 Billion JPY | 5.64% |
| 2006 | 920.62 Billion JPY | 4.69% |
| 2005 | 879.36 Billion JPY | 96.7% |
| 2004 | 447.05 Billion JPY | -12.55% |
| 2003 | 511.2 Billion JPY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 462.49 Billion JPY | -2.25% |
| 2024 Q1 | 473.12 Billion JPY | 14.12% |
| 2023 Q1 | 374.99 Billion JPY | 5.85% |
| 2023 Q2 | 392.14 Billion JPY | 4.58% |
| 2023 FY | 1603.67 Billion JPY | 5.6% |
| 2023 Q3 | 421.93 Billion JPY | 7.6% |
| 2023 Q4 | 414.6 Billion JPY | -1.74% |
| 2022 Q4 | 354.25 Billion JPY | -11.92% |
| 2022 Q2 | 380.39 Billion JPY | -0.37% |
| 2022 FY | 1518.61 Billion JPY | 17.16% |
| 2022 Q1 | 381.79 Billion JPY | 25.64% |
| 2022 Q3 | 402.18 Billion JPY | 5.73% |
| 2021 Q1 | 326.14 Billion JPY | 5.68% |
| 2021 Q2 | 325.52 Billion JPY | -0.19% |
| 2021 Q4 | 303.87 Billion JPY | -10.79% |
| 2021 FY | 1296.16 Billion JPY | 3.73% |
| 2021 Q3 | 340.62 Billion JPY | 4.64% |
| 2020 Q3 | 325.42 Billion JPY | 5.48% |
| 2020 FY | 1249.52 Billion JPY | -3.94% |
| 2020 Q1 | 306.96 Billion JPY | -1.71% |
| 2020 Q2 | 308.51 Billion JPY | 0.5% |
| 2020 Q4 | 308.62 Billion JPY | -5.16% |
| 2019 Q3 | 338.06 Billion JPY | 6.87% |
| 2019 FY | 1300.84 Billion JPY | -0.42% |
| 2019 Q1 | 334.13 Billion JPY | 10.89% |
| 2019 Q2 | 316.33 Billion JPY | -5.33% |
| 2019 Q4 | 312.3 Billion JPY | -7.62% |
| 2018 Q2 | 318.01 Billion JPY | -3.37% |
| 2018 Q3 | 357.93 Billion JPY | 12.55% |
| 2018 Q4 | 301.32 Billion JPY | -15.82% |
| 2018 FY | 1306.34 Billion JPY | 0.46% |
| 2018 Q1 | 329.08 Billion JPY | 9.38% |
| 2017 Q2 | 317.18 Billion JPY | -1.67% |
| 2017 FY | 1300.31 Billion JPY | -0.87% |
| 2017 Q4 | 300.87 Billion JPY | -16.35% |
| 2017 Q3 | 359.69 Billion JPY | 13.4% |
| 2017 Q1 | 322.57 Billion JPY | 5.39% |
| 2016 Q2 | 313.92 Billion JPY | -7.06% |
| 2016 Q4 | 306.07 Billion JPY | -13.52% |
| 2016 Q3 | 353.91 Billion JPY | 12.74% |
| 2016 Q1 | 337.75 Billion JPY | 10.0% |
| 2016 FY | 1311.66 Billion JPY | -4.45% |
| 2015 Q2 | 343.84 Billion JPY | 0.05% |
| 2015 Q1 | 343.65 Billion JPY | 16.7% |
| 2015 FY | 1372.7 Billion JPY | 10.06% |
| 2015 Q4 | 307.04 Billion JPY | -18.81% |
| 2015 Q3 | 378.16 Billion JPY | 9.98% |
| 2014 Q3 | 358.31 Billion JPY | 19.72% |
| 2014 Q2 | 299.29 Billion JPY | 1.4% |
| 2014 FY | 1247.25 Billion JPY | 9.42% |
| 2014 Q1 | 295.15 Billion JPY | 16.89% |
| 2014 Q4 | 294.48 Billion JPY | -17.81% |
| 2013 FY | 1139.9 Billion JPY | 13.35% |
| 2013 Q4 | 252.5 Billion JPY | -23.65% |
| 2013 Q3 | 330.7 Billion JPY | 17.75% |
| 2013 Q2 | 280.85 Billion JPY | 1.81% |
| 2013 Q1 | 275.84 Billion JPY | 10.16% |
| 2012 Q4 | 250.41 Billion JPY | -10.04% |
| 2012 FY | 1005.61 Billion JPY | 3.74% |
| 2012 Q1 | 243.23 Billion JPY | 18.35% |
| 2012 Q2 | 233.6 Billion JPY | -3.96% |
| 2012 Q3 | 278.36 Billion JPY | 19.16% |
| 2011 Q1 | 251.61 Billion JPY | 14.55% |
| 2011 Q2 | 232.3 Billion JPY | -7.67% |
| 2011 Q3 | 279.94 Billion JPY | 20.51% |
| 2011 Q4 | 205.51 Billion JPY | -26.59% |
| 2011 FY | 969.38 Billion JPY | 1.62% |
| 2010 Q4 | 219.66 Billion JPY | -19.4% |
| 2010 FY | 953.94 Billion JPY | -2.15% |
| 2010 Q1 | 237.49 Billion JPY | 17.51% |
| 2010 Q2 | 224.23 Billion JPY | -5.58% |
| 2010 Q3 | 272.55 Billion JPY | 21.55% |
| 2009 Q1 | 252.13 Billion JPY | 21.97% |
| 2009 Q2 | 242.5 Billion JPY | -3.82% |
| 2009 Q3 | 278.13 Billion JPY | 14.69% |
| 2009 Q4 | 202.09 Billion JPY | -27.34% |
| 2009 FY | 974.87 Billion JPY | 0.95% |
| 2008 FY | 965.69 Billion JPY | -0.71% |
| 2008 Q4 | 206.71 Billion JPY | -22.21% |
| 2008 Q3 | 265.72 Billion JPY | 11.32% |
| 2008 Q2 | 238.7 Billion JPY | 0.0% |
| 2007 FY | 972.58 Billion JPY | 5.64% |
| 2006 FY | 920.62 Billion JPY | 4.69% |
| 2005 FY | 879.36 Billion JPY | 96.7% |
| 2004 FY | 447.05 Billion JPY | -12.55% |
| 2003 FY | 511.2 Billion JPY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Kyowa Kirin Co., Ltd. | 442.23 Billion JPY | -262.631% |
| Chugai Pharmaceutical Co., Ltd. | 1111.36 Billion JPY | -44.297% |
| Ono Pharmaceutical Co., Ltd. | 502.67 Billion JPY | -219.03% |
| Santen Pharmaceutical Co., Ltd. | 301.96 Billion JPY | -431.079% |
| JCR Pharmaceuticals Co., Ltd. | 42.87 Billion JPY | -3640.692% |
| Daiichi Sankyo Company, Limited | 1601.68 Billion JPY | -0.124% |
| Otsuka Holdings Co., Ltd. | 2018.56 Billion JPY | 20.554% |
| Perseus Proteomics Inc. | 100.4 Million JPY | -1597151.051% |